Canagliflozin and iron metabolism in the CREDENCE trial.
Akihiko KoshinoHiddo J Lambers HeerspinkNiels JongsSunil V BadveClare ArnottBruce NealMeg JardineKenneth W MahaffeyCarol A PollockVlado PerkovicMichael K HansenStephan J L BakkerTakashi WadaBrendon L NeuenPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
Iron deficiency is highly prevalent in patients with type 2 diabetes and CKD. Canagliflozin increased TIBC and decreased ferritin in patients with T2D and CKD, suggesting increased iron utilization, and improved hemoglobin levels and clinical outcomes regardless of iron deficiency.